In our study, we analyzed the efficacy difference of neoadjuvant chemotherapy regimens in 240 breast cancer patients and found that patients with luminal A (1.6%) and luminal B (13.4%) types had the lowest pCR rates followed by HER2 overexpressing (22.6%) and triple negative (23.8%) types (Table 4). Here, ERBB2 is linked to breast carcinoma.